ライフサイエンスコーパス: dipeptidyl peptidase

1 ptides are orally bioavailable inhibitors of dipeptidyl peptidases.

2 tudies, CTL generated from mice deficient in dipeptidyl peptidase 1 (DPP1) were used to investigate t

3 Dipeptidyl peptidase 10 (DPP10) shares with DPP6 a high

4 We found that the cellular peptidases dipeptidyl peptidase 3 (DPP-3) and thimet oligopeptidase

5 ke WTX, PALB2, and SQSTM1, we found that the dipeptidyl peptidase 3 (DPP3) protein binds KEAP1 via an

6 as a mediator of the therapeutic effects of dipeptidyl peptidase 4 (DPP-4) inhibition (vildagliptin)

7 n), was identified as a potent and selective dipeptidyl peptidase 4 (DPP-4) inhibitor with an excelle

8 perglycemic agents, including saxagliptin, a dipeptidyl peptidase 4 (DPP-4) inhibitor, are unclear.

9 antidiabetic incretin-based drugs, including dipeptidyl peptidase 4 (DPP-4) inhibitors and glucagon-l

10 outcomes with alogliptin, a new inhibitor of dipeptidyl peptidase 4 (DPP-4), as compared with placebo

11 omaltase, glucose transporter 2 (GLUT2), and dipeptidyl peptidase 4 (DPP-4), as well as that of the p

12 Previous analysis of mice lacking the enzyme dipeptidyl peptidase 4 (DPP4(-/-) mice), a biomedically

13 ted proteins such as the tetraspanin CD9 and dipeptidyl peptidase 4 (DPP4) along with multiple endoso

14 ory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an entry receptor.

15 ory syndrome coronavirus (MERS-CoV) utilizes dipeptidyl peptidase 4 (DPP4) as an entry receptor.

16 r (Gipr)-deficient mice receiving background dipeptidyl peptidase 4 (DPP4) inhibitor treatment were c

17 However, whether increased dipeptidyl peptidase 4 (DPP4) is involved in the pathoge

18 Dipeptidyl peptidase 4 (DPP4) is the receptor for cell b

19 MERS-CoV to the cell surface entry receptor dipeptidyl peptidase 4 (DPP4) occurs via S1(B) We now de

20 th Jamaican fruit bat (Artibeus jamaicensis) dipeptidyl peptidase 4 (DPP4) receptor and MERS-CoV repl

21 avirus (MERS-CoV) binds to cellular receptor dipeptidyl peptidase 4 (DPP4) via the spike (S) protein

22 Recently, the MERS-CoV receptor dipeptidyl peptidase 4 (DPP4) was identified and the spe

23 ions with the MERS-CoV cell surface receptor dipeptidyl peptidase 4 (DPP4), and evolutionary mechanis

24 receptor for MERS-CoV has been identified as dipeptidyl peptidase 4 (DPP4), the mouse DPP4 homologue

25 Liver microfragments from dipeptidyl peptidase 4 (DPP4)-deficient rats were transp

26 Taken together, our results point toward dipeptidyl peptidase 4 (DPP4)-dependent endosomal uptake

27 binding of the RBD to its cellular receptor, dipeptidyl peptidase 4 (DPP4).

28 , 4, 5, 13, and 14; sucrase isomaltase (SI); dipeptidyl peptidase 4 (Dpp4); glucose transporter type

29 Dipeptidyl peptidase 4 (DPP4, CD26) is a protease that c

30 Dipeptidyl peptidase 4 (DPP4, CD26), a type II transmemb

31 hree different epitopes in the RBD and human dipeptidyl peptidase 4 (hDPP4) interface with subnanomol

32 V after adenovirus transduction of the human dipeptidyl peptidase 4 (hDPP4) receptor and then analyze

33 Human dipeptidyl peptidase 4 (hDPP4) was recently identified a

34 ike peptide 1 [GLP-1] analogue) or enhancer (dipeptidyl peptidase 4 [DPP4] inhibitor).

35 t cells were identified as a major source of dipeptidyl peptidase 4 and we also found that skin mast

36 We further show dipeptidyl peptidase 4 expression, MERS-CoV replication,

37 Previous trial results have suggested that dipeptidyl peptidase 4 inhibitor (DPP4i) use might incre

38 rdiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patie

39 ascular safety of alogliptin, a nonselective dipeptidyl peptidase 4 inhibitor.

40 Dipeptidyl peptidase 4 inhibitors had an increased risk

41 ingestion and is critical for the actions of dipeptidyl peptidase 4 inhibitors that enhance GLP-1 lev

42 ike peptide 1 mimetics, amylin mimetics, and dipeptidyl peptidase 4 inhibitors), in addition to diet

43 nd 330) that match the human sequence in the dipeptidyl peptidase 4 receptor, making mice susceptible

44 MERS-CoV antigen; double immunostaining with dipeptidyl peptidase 4 showed colocalization in scattere

45 Dipeptidyl peptidase 4 was found to be expressed in mast

46 der enzymes (lactase, sucrase-isomaltase and dipeptidyl peptidase 4) and visible subepithelial and sm

47 ss spectrometry analysis revealed that DPP4 (dipeptidyl peptidase 4) was selectively expressed on the

48 corresponding oxopeptides toward cleavage by dipeptidyl peptidase 4, the principal regulator of their

49 lmonary expression of the MERS-CoV receptor, dipeptidyl peptidase 4, was similar in marmosets and mac

50 ns, the neural cell adhesion molecule L1 and dipeptidyl peptidase 4, were further studied.

51 of incretin mimetic drugs and inhibitors of dipeptidyl peptidase 4, which degrades GLP-1.

52 Trials of inhibitors of dipeptidyl peptidase 4, which enhance the effect of endo

53 itute or an inhibitor of the serine protease dipeptidyl peptidase 4.

54 cludens-1, mucins-1 and -2, antigen A33, and dipeptidyl peptidase 4.

55 stasis: neural cell adhesion molecule L1 and dipeptidyl peptidase 4.

56 romal cell-derived factor-1-degrading enzyme dipeptidyl peptidase 4.

57 tors expressing the human host-cell receptor dipeptidyl peptidase 4.

58 glucosyltransferase); butyrylcholinesterase; dipeptidyl-peptidase 4 (CD26, adenosine deaminase comple

59 Dipeptidyl-peptidase 4 (DPP-4) inhibitors are increasing

60 Acarbose, the dipeptidyl-peptidase 4-inhibitor sitagliptin, the glucag

61 Dipeptidyl peptidase-4 (CD26, DPP4) inhibitors are the m

62 Dipeptidyl peptidase-4 (DDP4) inhibitors target the enzy

63 te effects of treatment with vildagliptin on dipeptidyl peptidase-4 (DPP-4) activity, glucagon-like p

64 nes are terminated via enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4) and through renal clearan

65 Fibroblast activation protein (FAP) and dipeptidyl peptidase-4 (DPP-4) are highly homologous ser

66 nguish FAP from other prolyl peptidases like dipeptidyl peptidase-4 (DPP-4) have not been developed.

67 (GLP-1) receptor agonists and inhibitors of dipeptidyl peptidase-4 (DPP-4) have shown pleiotropic ef

68 in this subgroup who also had baseline serum dipeptidyl peptidase-4 (DPP-4) higher than the populatio

69 od, crossover study in 24 patients with T2D, dipeptidyl peptidase-4 (DPP-4) inhibition and its glucos

70 bese mice (ob/ob), 45h was as effective as a dipeptidyl peptidase-4 (DPP-4) inhibitor at reducing pea

71 Linagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor in clinical use

72 Linagliptin is a dipeptidyl Peptidase-4 (DPP-4) inhibitor that inhibits t

73 In this regard, dipeptidyl peptidase-4 (DPP-4) inhibitors have recently

74 acological levels of GLP-1 activity, whereas dipeptidyl peptidase-4 (DPP-4) inhibitors increase conce

75 1 (GLP-1) secretion, on glucose lowering by dipeptidyl peptidase-4 (DPP-4) inhibitors is unclear.

76 Dipeptidyl peptidase-4 (DPP-4) inhibitors prevent degrad

77 Recent studies concluded that dipeptidyl peptidase-4 (DPP-4) inhibitors provide glycem

78 ike peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors represent 2 di

79 etformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 (DPP-4) inhibitors, and sodium-gl

80 italized heart failure (hHF) associated with dipeptidyl peptidase-4 (DPP-4) inhibitors, creating unce

81 GLP-1 receptor agonists (GLP-1 RAs) and dipeptidyl peptidase-4 (DPP-4) inhibitors, which inhibit

82 bute to the mechanism by which inhibitors of dipeptidyl peptidase-4 (DPP-4) lower postprandial glucos

83 on of enzymatic degradation by inhibition of dipeptidyl peptidase-4 (DPP-4) promotes glycemic reducti

84 ears to prevent apoptosis, and inhibition of dipeptidyl peptidase-4 (DPP-4), which cleaves GLP-1, is

85 GLP-1 and GLP-2 are both cleaved by dipeptidyl peptidase-4 (DPP-4); hence, inhibition of DPP

86 nfect both humans and dromedary camels using dipeptidyl peptidase-4 (DPP4) as its receptor.

87 icyte interactions, as well as the effect of dipeptidyl peptidase-4 (DPP4) inhibitor on CD in endothe

88 The incretin-based therapies, dipeptidyl peptidase-4 (DPP4) inhibitors and glucagon-li

89 viously disclosed azolopyrimidine containing dipeptidyl peptidase-4 (DPP4) inhibitors led us to focus

90 Dipeptidyl peptidase-4 (DPP4) inhibitors used for the tr

91 Dipeptidyl peptidase-4 (DPP4) was recently identified as

92 Blocking dipeptidyl peptidase-4 activity resulted in decreased po

93 gon like peptide-1 levels and a reduction in dipeptidyl peptidase-4 activity.

94 antidiabetic agents such as sulfonylureas or dipeptidyl peptidase-4 antagonists, which promote glucos

95 We investigated whether chronic dipeptidyl peptidase-4 inhibition by sitagliptin protect

96 At 30 minutes recovery, dipeptidyl peptidase-4 inhibition mitigated the postisch

97 dy, we compared the safety and efficacy of a dipeptidyl peptidase-4 inhibitor (sitagliptin) plus basa

98 adverse events for those associated with the dipeptidyl peptidase-4 inhibitor sitagliptin and the glu

99 The dipeptidyl peptidase-4 inhibitor sitagliptin, an antidia

100 The addition of dipeptidyl peptidase-4 inhibitor therapy with sitaglipti

101 creasing thiazolidinedione use and increased dipeptidyl peptidase-4 inhibitor use over time (P<0.001)

102 f newer antihyperglycemic medications in the dipeptidyl peptidase-4 inhibitor, glucagon-like peptide-

103 o assess the effectiveness of linagliptin, a dipeptidyl peptidase-4 inhibitor, in elderly patients wi

104 gonist, versus maximum approved doses of the dipeptidyl peptidase-4 inhibitor, sitagliptin, or the th

105 CI 1.15-1.76; six trials), intermediate with dipeptidyl peptidase-4 inhibitors (1.25, 1.08-1.45; two

106 ndings from preclinical studies suggest that dipeptidyl peptidase-4 inhibitors and proton-pump inhibi

107 ials supporting the cardiovascular safety of dipeptidyl peptidase-4 inhibitors and some glucagon-like

108 lucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors are commonly used for

109 There are also concerns that dipeptidyl peptidase-4 inhibitors could cause cancer, gi

110 ncretin system, GLP-1 receptor agonists, and dipeptidyl peptidase-4 inhibitors for 26 +/- 8 months be

111 1 analogs, alpha-glucosidase inhibitors, and dipeptidyl peptidase-4 inhibitors were associated with w

112 diones were used in 6.6% of HF patients, and dipeptidyl peptidase-4 inhibitors were used in 5.1%, wit

113 n-like peptide [GLP]-1 receptor agonists and dipeptidyl peptidase-4 inhibitors) have proven efficacy

114 s continued taking metformin with or without dipeptidyl peptidase-4 inhibitors.

115 the glucagon-like peptide-1 mimetics and the dipeptidyl peptidase-4 inhibitors.

116 t for 6-12 months and once-weekly tablets of dipeptidyl peptidase-4 inhibitors.

117 essing enzyme corin and BNP-degrading enzyme dipeptidyl peptidase-4 were reduced in HF versus normal,

118 We identified a single protein, CD26 (dipeptidyl peptidase-4).

119 otentially by producing excessive amounts of Dipeptidyl peptidase-4, a protease that is a target of d

120 s augmented by pharmacological inhibition of dipeptidyl peptidase-4.

121 cluding CD103(+) and CD11b(hi) cDCs, express dipeptidyl peptidase-4/CD26.

122 inally, combination of DGAT1 inhibition with dipeptidyl-peptidase-4 (DPP-4) inhibition led to further

123 Fasting adipocytokines and dipeptidyl-peptidase-4 concentrations were measured.

124 Dipeptidyl-peptidase-4 levels increased after surgery (P

125 racting proteins (KChIPs) and transmembrane, dipeptidyl peptidase 6 and 10 (DPP6/10) accessory subuni

126 The dipeptidyl-peptidase 6 gene has been associated with a n

127 We report that dipeptidyl-peptidase 6 interacts with a filopodia-associ

128 Dipeptidyl-peptidase 6 is an auxiliary subunit of Kv4-me

129 We find that the hippocampal neurons lacking dipeptidyl-peptidase 6 show a sparser dendritic branchin

130 dipeptidyl-peptidase 6 therefore has an unexpected but i

131 we employ knockdown and genetic deletion of dipeptidyl-peptidase 6 to reveal its importance for the

132 including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8 (DPP8), fibroblast activation pro

133 Here we identified the cytosolic dipeptidyl peptidase 9 (DPP9) as a SUMO1 interacting pro

134 lose FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and prolyl oligopeptidase.

135 dies that significantly inhibited murine FAP dipeptidyl peptidase activity in vitro.

136 se in gelatinase activity, whereas levels of dipeptidyl peptidase activity remained unchanged.

137 Both proteases display dipeptidyl peptidase activity, but FAP alone has endopep

138 types of EDTA-resistant protease activities: dipeptidyl peptidase and a 170-kDa gelatinase activity.

139 FAP has been shown to have both in vitro dipeptidyl peptidase and collagenase activity, but its b

140 The data support increasing evidence that dipeptidyl peptidases can regulate complex biologic syst

141 Dipeptidyl peptidase-deficient F344 rats were preconditi

142 Dipeptidyl peptidases (DP) 8 and 9 are homologous, cytop

143 The dipeptidyl peptidase (DPP) 4 family includes four enzyme

144 The intracellular peptidases dipeptidyl peptidase (DPP) 8 and DPP9 are involved in mu

145 boronic dipeptide, PT-100 (Val-boro-Pro), a dipeptidyl peptidase (DPP) inhibitor, has been shown to

146 Dipeptidyl peptidase (DPP)-4 inhibition is a glucose-low

147 The binding kinetics and thermodynamics of dipeptidyl peptidase (DPP)-4 inhibitors (gliptins) were

148 Dipeptidyl peptidase (DPP)-IV inhibitory peptides were p

149 administration of an inhibitor of the enzyme dipeptidyl-peptidase (DPP4i), which prevents the cleavag

150 Like the closely related dipeptidyl peptidase DPPIV, the extracellular domain of

151 ncy and high selectivity against the related dipeptidyl peptidases (DPPs) DPPIV, DPP9, DPPII, and pro

152 DPP10 encodes a homolog of dipeptidyl peptidases (DPPs) that cleave terminal dipept

153 demonstrate that this effect is prevented by dipeptidyl peptidases (DPPs), which cleave NPY to its sh

154 ors that are selective for FAP over both the dipeptidyl peptidases (DPPs), with which it shares exope

155 f dipeptide production processes mediated by dipeptidyl-peptidases (DPPs) should be beneficial for th

156 l-peptidase IV/CD26 and lactococcal x-prolyl dipeptidyl-peptidase families.

157 s and Lactococcus spp. and putative x-prolyl dipeptidyl-peptidases from other streptococcal species.

158 rectly inhibits the activity of MMP20, KLK4, dipeptidyl peptidase I (DPPI) (an in vitro activator of

159 The cysteine protease dipeptidyl peptidase I (DPPI) activates granule-associat

160 lammation, we generated a mouse deficient in dipeptidyl peptidase I (DPPI) and established that DPPI

161 Dipeptidyl peptidase I (DPPI) is a cysteine aminopeptida

162 Dipeptidyl peptidase I (DPPI) is a cysteine protease req

163 Dipeptidyl peptidase I (DPPI) is a lysosomal cysteine pr

164 Dipeptidyl peptidase I (DPPI) is the sole activator in v

165 e injected TxA into ileal loops in PAR(2) or dipeptidyl peptidase I (DPPI) knockout mice or in wild-t

166 In this study, we show that the absence of dipeptidyl peptidase I (DPPI), a lysosomal cysteine prot

167 the lysosomal cysteine protease cathepsin C/dipeptidyl peptidase I (DPPI).

168 Cathepsin C, or dipeptidyl peptidase I, is a lysosomal cysteine protease

169 n inactivating mutation in the gene encoding dipeptidyl peptidase I, resulting in neutrophils lacking

170 aring features like propeptide processing by dipeptidyl peptidase I, storage, and release as an activ

171 as not delayed in perforin-deficient mice or dipeptidyl peptidase I-deficient mice, which fail to pro

172 Dipeptidyl peptidase III (DPP III) is one of the most im

173 CD26/dipeptidyl peptidase is responsible for serum cleavage o

174 an unusual substrate specificity shared with dipeptidyl peptidase IV (CD26/DPPIV).

175 CD26 or dipeptidyl peptidase IV (DP IV) is expressed on various

176 Dipeptidyl peptidase IV (DP-IV) is a cell surface serine

177 Dipeptidyl peptidase IV (DP-IV), a member of the prolyl

178 6)PAL) and GIP(Lys(37)PAL) were resistant to dipeptidyl peptidase IV (DPP IV) degradation.

179 Dipeptidyl peptidase IV (DPP IV) is a ubiquitous membran

180 Binding of plasminogen type II (Pg 2) to dipeptidyl peptidase IV (DPP IV) on the surface of the h

181 method to a variety of proteases, including dipeptidyl peptidase IV (DPP IV), dipeptidyl peptidase 8

182 ained lactam aminoboronic acid inhibitors of dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).

183 gorous steady state enzyme kinetic assay for dipeptidyl peptidase IV (DPP IV; E.C. 3.4.14.5).

184 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-4) for the treatment of typ

185 novel aminopiperidine-fused imidazopyridine dipeptidyl peptidase IV (DPP-4) inhibitor 1 has been dev

186 ered as potent, selective, and orally active dipeptidyl peptidase IV (DPP-4) inhibitors by extensive

187 Dipeptidyl peptidase IV (DPP-IV) belongs to a family of

188 Dipeptidyl peptidase IV (DPP-IV) degrades the incretin h

189 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty

190 e synthesized and evaluated as inhibitors of dipeptidyl peptidase IV (DPP-IV) for the treatment of ty

191 agon-like peptide-1 (GLP-1) degrading enzyme dipeptidyl peptidase IV (DPP-IV) have been shown to be e

192 Xanthine oxidase (XO) and dipeptidyl peptidase IV (DPP-IV) inhibition by amino aci

193 Dipeptidyl peptidase IV (DPP-IV) inhibition has the pote

194 acid linked l-cis-4,5-methanoprolinenitrile dipeptidyl peptidase IV (DPP-IV) inhibitors led to the i

195 tent angiotensin converting enzyme (ACE) and dipeptidyl peptidase IV (DPP-IV) inhibitory and oxygen r

196 Nine novel dipeptidyl peptidase IV (DPP-IV) inhibitory peptides (FL

197 ts (DOE) was used to optimise the release of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides dur

198 of 72 dietary proteins to act as a source of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides.

199 as no significant effect of pH regulation on dipeptidyl peptidase IV (DPP-IV) properties.

200 These peptides are known to act as preferred dipeptidyl peptidase IV (DPP-IV) substrates.

201 l screening was performed against the target dipeptidyl peptidase IV (DPP-IV) to identify good chemic

202 HSA), other components, such as the protease dipeptidyl peptidase IV (DPP-IV), possibly contribute to

203 N-terminal sequence-specific serine protease dipeptidyl peptidase IV (DPP-IV).

204 Dipeptidyl peptidase IV (DPP-IV; E.C. 3.4.14.5), a serin

205 Dipeptidyl peptidase IV (DPP4) deactivates glucose-regul

206 Dipeptidyl peptidase IV (DPP4) inhibitors are emerging a

207 Dipeptidyl peptidase IV (DPP4/CD26) and seprase/fibrobla

208 ing of the purified protein identified it as dipeptidyl peptidase IV (DPPIV) (EC ), which was confirm

209 Dipeptidyl peptidase IV (DPPIV) activity was quantified

210 , we treated Fischer 344 (F344) rats lacking dipeptidyl peptidase IV (DPPIV) activity with cyclophosp

211 (r) 110,000 surface-bound ectopeptidase with dipeptidyl peptidase IV (DPPIV) activity, has an array o

212 epatocytes can give rise to SHPCs, rats with dipeptidyl peptidase IV (DPPIV) chimeric livers, which h

213 expression of CD26, especially its intrinsic dipeptidyl peptidase IV (DPPIV) enzyme activity, results

214 ine (C5-Pro-Pro) analogues was discovered as dipeptidyl peptidase IV (DPPIV) inhibitors as a potentia

215 Dipeptidyl peptidase IV (DPPIV) is a serine protease wit

216 as evaluated by injecting cell isolates from dipeptidyl peptidase IV (DPPIV) positive (DPPIV+) Fische

217 Dipeptidyl peptidase IV (DPPIV), a cell surface serine p

218 ddresses the hypothesis that the activity of dipeptidyl peptidase IV (DPPIV), an enzyme that inactiva

219 expression of a cell transplantation marker, dipeptidyl peptidase IV (DPPIV), and GFP.

220 membrane-bound prolyl peptidases seprase and dipeptidyl peptidase IV (DPPIV), at invadopodia of migra

221 transplanted intrasplenically into syngeneic dipeptidyl peptidase IV (DPPIV)-deficient rats.

222 FAPalpha exhibits a dipeptidyl peptidase IV (DPPIV)-like fold, featuring an

223 g the protocol of injecting hepatocytes from dipeptidyl peptidase IV (DPPIV)-positive donors into ret

224 ffects of HIR on engraftment of transplanted dipeptidyl peptidase IV (DPPIV)-positive hepatocytes in

225 rotein (FAP) is a serine protease related to dipeptidyl peptidase IV (DPPIV).

226 ed structure of AprA has similarity to human dipeptidyl peptidase IV (DPPIV).

227 y inhibition of the closely related protease dipeptidyl peptidase IV (DPPIV).

228 proteins after enzymatic digestion, against dipeptidyl peptidase IV (DPPIV); an enzyme known to deac

229 ied throughout a 6-month period in syngeneic dipeptidyl peptidase IV (DPPIV-) mutant F344 rats.

230 Lung endothelial dipeptidyl peptidase IV (DPPIV/CD26) is a vascular addre

231 Wild-type (dipeptidyl peptidase IV [DPPIV(+)]) embryonic day (ED) 1

232 hepatocyte colonies with strong canalicular dipeptidyl peptidase IV activity.

233 atrophy and marked up-regulation of mucosal dipeptidyl peptidase IV and PepT1 messenger RNA.

234 tology and expression of brush border enzyme dipeptidyl peptidase IV and peptide transporter PepT1 me

235 both analogues were completely resistant to dipeptidyl peptidase IV degradation.

236 assays based on F344 recipient rats lacking dipeptidyl peptidase IV enzyme activity to identify tran

237 ibited APCE with a K(i) of 54 microM but not dipeptidyl peptidase IV even at 2 mM.

238 brush border Na(+)-H(+) exchanger NHE3 with dipeptidyl peptidase IV in the proximal tubule.

239 vivo, but this effect was only detected with dipeptidyl peptidase IV inhibition, while mucosal respon

240 ulocyte-colony stimulating factor (G-CSF), a dipeptidyl peptidase IV inhibitor (DPP-4i), and a proton

241 in medicinal chemistry applications such as dipeptidyl peptidase IV inhibitors.

242 tal liver cells were transplanted into adult dipeptidyl peptidase IV knockout mice and differentiated

243 One week post-MMC treatment, dipeptidyl peptidase IV negative host rats were given a

244 vivo and mature into hepatocytes expressing dipeptidyl peptidase IV or fumarylacetoacetate hydrolase

245 ntained large clusters of sinusoids lined by dipeptidyl peptidase IV positive endothelial cells coexp

246 newborn, or adult total liver isolates from dipeptidyl peptidase IV positive rats.

247 nd possible site of USF interaction with the dipeptidyl peptidase IV promoter was localized to the -1

248 ent on degradation by neutral endopeptidase, dipeptidyl peptidase IV, and aminopeptidase P.

249 ts but does not inhibit close FAP homologues dipeptidyl peptidase IV, dipeptidyl peptidase 9, and pro

250 Three groups of mutant F344 dipeptidyl peptidase IV-deficient (DPPIV(-)) rats were r

251 , we used transplanted cells as reporters in dipeptidyl peptidase IV-deficient mice.

252 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats followed by histo

253 Dipeptidyl peptidase IV-deficient rats were used as reci

254 ter transplanting syngeneic hepatocytes into dipeptidyl peptidase IV-deficient rats.

255 t and proliferation of transplanted cells in dipeptidyl peptidase IV-deficient rats.

256 hepatocytes were transplanted into syngeneic dipeptidyl peptidase IV-deficient rats.

257 d Fischer 344 rat hepatocytes into syngeneic dipeptidyl peptidase IV-deficient rats.

258 F344 rat hepatocytes with or without DAR in dipeptidyl peptidase IV-deficient rats.

259 r repopulation by histochemical staining for dipeptidyl peptidase IV.

260 ll surface multifunctional glycoprotein CD26/dipeptidyl peptidase IV.

261 curs bound to the membrane glycoprotein CD26/dipeptidyl peptidase IV.

262 complex with the cell membrane protein CD26/dipeptidyl peptidase IV.

263 gelatinase that is related to the ectoenzyme dipeptidyl peptidase IV.

264 n, expression of sucrase isomaltase (SI) and dipeptidyl-peptidase IV (DPP-IV), two well known intesti

265 ow cytometry and histochemical estimation of dipeptidyl-peptidase IV enzyme activity of donor cells i

266 nzymatic activity of molecules such as CD26 (dipeptidyl-peptidase IV), which may act by metabolizing

267 in juvenile and senescent rats deficient in dipeptidyl-peptidase IV.

268 l specificity that is comparable to both the dipeptidyl-peptidase IV/CD26 and lactococcal x-prolyl di

269 -glucosidase (37.8%), alpha-amylase (35.6%), dipeptidyl peptidase-IV (34.4%), reactive oxygen species

270 uggest a variety of bioactivities, including dipeptidyl peptidase-IV (DPP-IV) and angiotensin convert

271 wever, its rapid degradation by enzymes like dipeptidyl peptidase-IV (DPP-IV) and neutral endopeptida

272 P-1 is short because of rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

273 f GLP-1 is short due to rapid degradation by dipeptidyl peptidase-IV (DPP-IV) and renal clearance.

274 Dipeptidyl peptidase-IV (DPP-IV) inhibitors are poised t

275 Dipeptidyl peptidase-IV (DPP-IV) is a serine protease in

276 P-1, due to its resistance to degradation by dipeptidyl peptidase-IV (DPP-IV).

277 ate or propionate increased DBS, enhanced by dipeptidyl peptidase-IV (DPPIV) inhibition, at the same

278 s are a good source of natural inhibitors of dipeptidyl peptidase-IV and prolyl endopeptidase and cou

279 The dipeptidyl peptidase-IV inhibitor saxagliptin (Onglyza)

280 tivities and clinical variants, for example, dipeptidyl peptidase-IV inhibitor-associated noninflamma

281 d 1-beta-fructofuranosyl nystose) are potent dipeptidyl peptidase-IV inhibitors as well as peroxisome

282 ction of several serine proteases, including dipeptidyl peptidase-IV, neutrophil elastase, matrix met

283 Dipeptidyl-peptidase-IV-deficient female rats received B

284 yeast of Blastomyces dermatitidis elaborates dipeptidyl-peptidase IVA (DppIVA), a close mimic of the

285 Protein biochemistry has identified dipeptidyl peptidase-like protein 6 (DPP6) as an auxilia

286 Dipeptidyl peptidase-like protein 6 (DPP6) is an auxilia

287 , the Ca(2+) binding proteins KChIPs and the dipeptidyl peptidase-like proteins (DPPLs) DPP6 (also kn

288 +) channel-interacting proteins (KChIPs) and dipeptidyl peptidase-like proteins (DPPLs).

289 ) channel-interacting proteins (KChIPs), and dipeptidyl peptidase-like proteins (DPPLs).

290 cell-base experiments with Kv4.2 and several dipeptidyl-peptidase-like protein-6 (DPPX) plasmid const

291 metabotropic glutamate receptor 5 (mGluR5), dipeptidyl-peptidase-like protein-6 (DPPX), and gamma-am

292 mined the putative novel contribution of the dipeptidyl-peptidase-like protein-6 DPP6-S to the gamma

293 Kv channel-interacting proteins (KChIPs) and dipeptidyl-peptidase-like proteins (DPLs: DPP6 or DPPX,

294 hannel interacting proteins (KChIPs) and the dipeptidyl-peptidase-like proteins (DPPLs) DPPX (DPP6) a

295 ulating the biophysical properties of Kv4.2: dipeptidyl-peptidase-like type II transmembrane proteins

296 eptidase (Sg-xPDPP, for S. gordonii x-prolyl dipeptidyl-peptidase), produced in a pH-controlled batch

297 class dipeptidyl-aminopeptidase, an x-prolyl dipeptidyl-peptidase (Sg-xPDPP, for S. gordonii x-prolyl

298 Conversely, DPP-4 Asp663 stabilizes dipeptidyl peptidase substrate binding and permits tight

299 marked TSS energy for both endopeptidase and dipeptidyl peptidase substrates, and structural modeling

300 Dipeptidyl peptidase type IV (DppIV) enzymes are broadly